BIOXCEL THERAPEUTICS INC's ticker is BTAI and the CUSIP is 09075P105. A total of 118 filers reported holding BIOXCEL THERAPEUTICS INC in Q1 2021. The put-call ratio across all filers is 0.92 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $358,438 | -46.7% | 141,675 | +40.3% | 0.00% | – |
| Q2 2023 | $672,454 | +236.4% | 100,969 | +842.6% | 0.00% | – |
| Q1 2023 | $199,886 | +33.3% | 10,712 | -15.4% | 0.00% | – |
| Q3 2022 | $150,000 | -90.8% | 12,666 | -83.8% | 0.00% | -100.0% |
| Q1 2022 | $1,631,000 | +242.6% | 78,004 | +232.8% | 0.00% | – |
| Q4 2021 | $476,000 | -25.2% | 23,442 | +11.9% | 0.00% | – |
| Q3 2021 | $636,000 | -45.4% | 20,954 | -47.7% | 0.00% | – |
| Q2 2021 | $1,165,000 | -56.6% | 40,098 | -35.6% | 0.00% | -100.0% |
| Q1 2021 | $2,687,000 | -35.6% | 62,247 | -31.1% | 0.00% | -33.3% |
| Q4 2020 | $4,175,000 | -40.2% | 90,385 | -43.8% | 0.00% | -25.0% |
| Q3 2020 | $6,977,000 | +51.2% | 160,921 | +84.9% | 0.00% | +33.3% |
| Q2 2020 | $4,614,000 | +1830.5% | 87,033 | +713.5% | 0.00% | – |
| Q1 2020 | $239,000 | – | 10,698 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| APIS CAPITAL ADVISORS, LLC | 40,000 | $836,000 | 1.01% |
| ACT CAPITAL MANAGEMENT, LLC | 20,000 | $418,000 | 0.44% |
| Knoll Capital Management, LLC | 20,000 | $418,000 | 0.26% |
| Artemis Investment Management LLP | 1,428,228 | $29,855,000 | 0.24% |
| Rubric Capital Management LP | 268,528 | $5,615,000 | 0.20% |
| Virtus ETF Advisers LLC | 7,713 | $161,000 | 0.07% |
| BOOTHBAY FUND MANAGEMENT, LLC | 107,700 | $2,252,000 | 0.05% |
| PDT Partners, LLC | 28,031 | $586,000 | 0.05% |
| AllSquare Wealth Management LLC | 3,162 | $66,000 | 0.04% |
| Hennion & Walsh Asset Management, Inc. | 35,221 | $736,000 | 0.04% |